US4503035B1
(en)
|
1978-11-24 |
1996-03-19 |
Hoffmann La Roche |
Protein purification process and product
|
US4530901A
(en)
|
1980-01-08 |
1985-07-23 |
Biogen N.V. |
Recombinant DNA molecules and their use in producing human interferon-like polypeptides
|
US5231176A
(en)
|
1984-08-27 |
1993-07-27 |
Genentech, Inc. |
Distinct family DNA encoding of human leukocyte interferons
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4868103A
(en)
|
1986-02-19 |
1989-09-19 |
Enzo Biochem, Inc. |
Analyte detection by means of energy transfer
|
EP0246753B1
(en)
|
1986-04-22 |
1994-07-13 |
The Salk Institute For Biological Studies |
Fibroblast growth factor antagonists
|
US4843155A
(en)
|
1987-11-19 |
1989-06-27 |
Piotr Chomczynski |
Product and process for isolating RNA
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5468468A
(en)
|
1989-02-09 |
1995-11-21 |
The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services |
Method for making a monoclonal antibody, monoclonal antibodies to α PD
|
US5674685A
(en)
|
1990-06-11 |
1997-10-07 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
US5668264A
(en)
|
1990-06-11 |
1997-09-16 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
CA2097603A1
(en)
|
1990-12-21 |
1992-06-22 |
Roy H. L. Pang |
Biosynthetic pdgf antagonists
|
JPH06507543A
(en)
|
1991-01-31 |
1994-09-01 |
コア セラピューティクス,インコーポレイティド |
Extracellular domain of human platelet-derived growth factor receptor polypeptide
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
US5480883A
(en)
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
ES2108120T3
(en)
|
1991-05-10 |
1997-12-16 |
Rhone Poulenc Rorer Int |
MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
US5817310A
(en)
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
US5238950A
(en)
|
1991-12-17 |
1993-08-24 |
Schering Corporation |
Inhibitors of platelet-derived growth factor
|
CA2087413A1
(en)
|
1992-01-17 |
1993-07-18 |
Joseph R. Lakowicz |
Fluorescent energy transfer immunoassay
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
ATE295420T1
(en)
|
1992-02-06 |
2005-05-15 |
Chiron Corp |
MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
|
TW225528B
(en)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5620687A
(en)
|
1993-02-25 |
1997-04-15 |
Zymogenetics, Inc. |
Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
|
US5976534A
(en)
|
1993-02-25 |
1999-11-02 |
Zymogenetics, Inc. |
Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
|
EP0672035A1
(en)
|
1993-10-01 |
1995-09-20 |
Novartis AG |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5952304A
(en)
|
1993-10-22 |
1999-09-14 |
Trigen Limited |
Platelet-derived growth factor analogues
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JPH07133280A
(en)
|
1993-11-09 |
1995-05-23 |
Takeda Chem Ind Ltd |
Cephem compound, its production and antimicrobial composition
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
ES2109796T3
(en)
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
DERIVATIVES OF PIRROLOPIRIMIDILO WITH ANTIPROLIFERANTE EFFECT.
|
US5958942A
(en)
|
1994-07-15 |
1999-09-28 |
Takeda Chemical Industries, Ltd. |
Tricyclic nitrogen ring compounds, their production and use
|
CA2156767A1
(en)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Binding agent for growth factor
|
US5476851A
(en)
|
1994-09-08 |
1995-12-19 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
|
US5795910A
(en)
|
1994-10-28 |
1998-08-18 |
Cor Therapeutics, Inc. |
Method and compositions for inhibiting protein kinases
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
ES2150113T3
(en)
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
DERIVATIVES OF PIRAZOLE AND PROCEDURES FOR THE PREPARATION OF THE SAME.
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5723594A
(en)
|
1995-06-07 |
1998-03-03 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
DE69636656T2
(en)
|
1995-06-02 |
2007-10-04 |
Gilead Sciences, Inc., Foster City |
OLIGONUCLEOTIDE LIGANDS WITH HIGH AFFINITY FOR PDGF
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
US5618837A
(en)
|
1995-06-07 |
1997-04-08 |
Zymogenetics, Inc. |
PDGF antagonists III
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5731326A
(en)
|
1995-06-30 |
1998-03-24 |
Zymogenetics, Inc. |
PDGF antagonists II
|
TR199800012T1
(en)
|
1995-07-06 |
1998-04-21 |
Novartis Ag |
Pyrolopyrimidines and applications for preparation.
|
DK9500262U4
(en)
|
1995-07-07 |
1996-10-07 |
Bonus Energy As |
Bottom frame for wind turbine housing and wind turbine comprising the same
|
AR004010A1
(en)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
HETERO CYCLIC COMPOUNDS
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
KR19990066981A
(en)
|
1995-10-23 |
1999-08-16 |
윌리엄 뉴우 |
Therapeutic angiogenesis composition and method
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
ATE225343T1
(en)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
MATRIX METALLOPROTEASE INHIBITORS
|
WO1997027199A1
(en)
|
1996-01-23 |
1997-07-31 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(en)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
Silicone rubber composition
|
CH690773A5
(en)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo (2,3-d) pyrimides and their use.
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
CA2244897C
(en)
|
1996-03-05 |
2006-04-11 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
DE19629652A1
(en)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation
|
DE19608588A1
(en)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation
|
CA2249739A1
(en)
|
1996-03-15 |
1997-09-25 |
Novartis Ag |
Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use
|
US5882644A
(en)
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
BR9708640B1
(en)
|
1996-04-12 |
2013-06-11 |
|
irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them.
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
CA2258548C
(en)
|
1996-06-24 |
2005-07-26 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
AU2710597A
(en)
|
1996-06-27 |
1998-01-14 |
Pfizer Inc. |
Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
DE69716916T2
(en)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd |
CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19430A
(en)
|
1996-07-13 |
1998-07-09 |
Glaxo Group Ltd |
COMPOUND HETEROSICLIC COMPOUND
|
JP3299975B2
(en)
|
1996-07-18 |
2002-07-08 |
ファイザー・インク |
Phosphinate-based inhibitors of matrix metalloproteases
|
DE69738468T2
(en)
|
1996-08-23 |
2009-01-08 |
Novartis Ag |
SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
|
US6153609A
(en)
|
1996-08-23 |
2000-11-28 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
CA2239227C
(en)
|
1996-10-01 |
2007-10-30 |
Kenji Matsuno |
Nitrogen-containing heterocyclic compounds
|
WO1998014450A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
ID18494A
(en)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
ATE272640T1
(en)
|
1997-01-06 |
2004-08-15 |
Pfizer |
CYCLIC SULFONE DERIVATIVES
|
IL131042A
(en)
|
1997-02-03 |
2004-07-25 |
Pfizer Prod Inc |
Arylsulfonylamino hydroxamic acid derivatives and pharmaceutical compositions comprising them
|
EP0964864B1
(en)
|
1997-02-05 |
2008-04-09 |
Warner-Lambert Company LLC |
Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
US5945422A
(en)
|
1997-02-05 |
1999-08-31 |
Warner-Lambert Company |
N-oxides of amino containing pyrido 2,3-D! pyrimidines
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
TR199901926T2
(en)
|
1997-02-11 |
1999-12-21 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
EP0984930B1
(en)
|
1997-05-07 |
2005-04-06 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6180632B1
(en)
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6159978A
(en)
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6245760B1
(en)
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
AU734009B2
(en)
|
1997-05-30 |
2001-05-31 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
NZ502309A
(en)
|
1997-08-08 |
2002-02-01 |
Pfizer Prod Inc |
Aryloxyarylsulfonylamino hydroxamic acid derivatives and pharmaceutical use
|
US6294532B1
(en)
|
1997-08-22 |
2001-09-25 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
JP2001518470A
(en)
|
1997-09-26 |
2001-10-16 |
メルク エンド カムパニー インコーポレーテッド |
Novel angiogenesis inhibitors
|
CN1280580A
(en)
|
1997-11-11 |
2001-01-17 |
辉瑞产品公司 |
Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents
|
US5932580A
(en)
|
1997-12-01 |
1999-08-03 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds their preparation and compositions
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
JPH11236333A
(en)
|
1997-12-30 |
1999-08-31 |
Pfizer Prod Inc |
Imidazolin-4-one derivative as anticancer agent
|
RS49779B
(en)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
PA8469401A1
(en)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
BICYCLE DERIVATIVES OF HYDROXAMIC ACID
|
PA8469501A1
(en)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
|
EP1082305A4
(en)
|
1998-05-29 |
2001-09-26 |
Sugen Inc |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(en)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
|
US6566131B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad6 expression
|
EE200100118A
(en)
|
1998-08-27 |
2002-06-17 |
Pfizer Products Inc. |
Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
|
CA2341739C
(en)
|
1998-08-27 |
2005-07-12 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
WO2000015781A1
(en)
|
1998-09-11 |
2000-03-23 |
Eli Lilly And Company |
Antagonists of fibroblast growth factor
|
US6410323B1
(en)
|
1999-08-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of human Rho family gene expression
|
ID29028A
(en)
|
1998-09-18 |
2001-07-26 |
Basf Ag |
PIROLOPIRIMIDINA AS A PROTEIN OF INHINING PROTEIN
|
DK1004578T3
(en)
|
1998-11-05 |
2004-06-28 |
Pfizer Prod Inc |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
EP1006113A1
(en)
|
1998-12-02 |
2000-06-07 |
Pfizer Products Inc. |
Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
|
US6107091A
(en)
|
1998-12-03 |
2000-08-22 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of G-alpha-16 expression
|
US5981732A
(en)
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
US6337338B1
(en)
|
1998-12-15 |
2002-01-08 |
Telik, Inc. |
Heteroaryl-aryl ureas as IGF-1 receptor antagonists
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(en)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
Heteroaromatic bicyclic derivatives useful as anticancer agents
|
AU3224700A
(en)
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
EP1150973B1
(en)
|
1999-02-11 |
2005-06-15 |
Pfizer Products Inc. |
Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
|
US6586447B1
(en)
|
1999-04-01 |
2003-07-01 |
Pfizer Inc |
3,3-disubstituted-oxindole derivatives useful as anticancer agents
|
US6046321A
(en)
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
DK1183033T3
(en)
|
1999-05-21 |
2006-06-06 |
Bristol Myers Squibb Co |
Pyrrolotriazine Inhibitors of Kinases
|
US6455525B1
(en)
|
1999-11-04 |
2002-09-24 |
Cephalon, Inc. |
Heterocyclic substituted pyrazolones
|
US6358954B1
(en)
|
1999-11-09 |
2002-03-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
ATE259365T1
(en)
|
1999-11-30 |
2004-02-15 |
Pfizer Prod Inc |
QUINOLINE DERIVATIVES USABLE FOR INHIBITING FARNESYL-PROTEIN TRANSFERASE
|
UA75055C2
(en)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
|
HN2000000266A
(en)
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
ANTI-TARGET COMPOUND AND METHOD OF SEPARATION OF ENANTIOMERS USEFUL TO SYNTHEIZE SUCH COMPOUND.
|
JP2003526367A
(en)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
RNA interference method and RNA interference composition
|
AU2001252940A1
(en)
|
2000-03-22 |
2001-10-03 |
Amgen Inc. |
Fibroblast growth factor receptor-like molecules and uses thereof
|
TWI310684B
(en)
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
WO2001072751A1
(en)
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
US6365354B1
(en)
|
2000-07-31 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of lysophospholipase I expression
|
ATE408613T1
(en)
|
2000-08-04 |
2008-10-15 |
Warner Lambert Co |
2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO(2,3-D)PYRIMIDINE-7-ONE
|
US6566135B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of caspase 6 expression
|
AR035885A1
(en)
|
2001-05-14 |
2004-07-21 |
Novartis Ag |
DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
|
SE0102168D0
(en)
|
2001-06-19 |
2001-06-19 |
Karolinska Innovations Ab |
New use and new compounds
|
WO2002102973A2
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
FR2828601B1
(en)
|
2001-08-10 |
2003-11-07 |
Iroc Technologies |
ELECTRONIC CIRCUIT ASSEMBLY COMPRISING MEANS FOR DECONTAMINATION OF PARTS CONTAMINATED BY ERRORS
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
IL160915A0
(en)
|
2001-09-19 |
2004-08-31 |
Aventis Pharma Sa |
Indolizines inhibiting kinase proteins
|
CA2460587A1
(en)
|
2001-09-20 |
2003-03-27 |
Alexion Pharmaceuticals, Inc. |
Anti-pdgf antibodies and methods for producing engineered antibodies
|
WO2003035614A2
(en)
|
2001-10-25 |
2003-05-01 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
AU2002348020A1
(en)
|
2001-10-25 |
2003-05-06 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
AU2002348394A1
(en)
|
2001-10-25 |
2003-05-06 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
WO2003035619A1
(en)
|
2001-10-25 |
2003-05-01 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
SE0104140D0
(en)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
AU2003205768A1
(en)
|
2002-02-14 |
2003-09-04 |
Dana-Farber Cancer Institute Inc. |
Methods and compositions for treating hyperproliferative conditions
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
CA2484000A1
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
TW200406374A
(en)
|
2002-05-29 |
2004-05-01 |
Novartis Ag |
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
|
TW200401638A
(en)
|
2002-06-20 |
2004-02-01 |
Bristol Myers Squibb Co |
Heterocyclic inhibitors of kinases
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
EP1543009A4
(en)
|
2002-08-02 |
2007-08-08 |
Bristol Myers Squibb Co |
Pyrrolotriazine kinase inhibitors
|
US7084270B2
(en)
|
2002-08-14 |
2006-08-01 |
Hoffman-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
US7112676B2
(en)
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
RU2340618C2
(en)
|
2002-11-18 |
2008-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Diazinopyrimidines and pharmaceutical composition containing them
|
TWI299664B
(en)
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
US7696225B2
(en)
|
2003-01-06 |
2010-04-13 |
Osi Pharmaceuticals, Inc. |
(2-carboxamido)(3-Amino) thiophene compounds
|
US6861208B2
(en)
|
2003-03-18 |
2005-03-01 |
The United States Of America As Represented By The Secretary Of The Army |
Fullerene addition in photoresist via incorporation in the developer
|
BRPI0409366A
(en)
|
2003-04-10 |
2006-04-25 |
Hoffmann La Roche |
pyrimidine compounds
|
US7253166B2
(en)
|
2003-04-22 |
2007-08-07 |
Irm Llc |
6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
|
CN1860118A
(en)
|
2003-07-29 |
2006-11-08 |
Irm责任有限公司 |
Compounds and compositions as protein kinase inhibitors
|
AP2006003549A0
(en)
|
2003-08-21 |
2006-04-30 |
Osi Pharm Inc |
N-substituted benzimidazolyl C-kit inhibitors.
|
CA2536174A1
(en)
|
2003-08-21 |
2005-03-10 |
Osi Pharmaceuticals, Inc. |
N3-substituted imidazopyridine-derivatives as c-kit inhibitors
|
AP2006003553A0
(en)
|
2003-08-21 |
2006-04-30 |
Osi Pharm Inc |
N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
|
DE10342503A1
(en)
|
2003-09-12 |
2005-04-14 |
Merck Patent Gmbh |
Benzyl-Benzimidazolylderivate
|
AP2006003620A0
(en)
|
2003-10-15 |
2006-06-30 |
Osi Pharm Inc |
Imidazopyrazine tyroshine kinase inhibitors
|
AR046639A1
(en)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
|
DE10356579A1
(en)
|
2003-12-04 |
2005-07-07 |
Merck Patent Gmbh |
amine derivatives
|
AU2004312376A1
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
MXPA06011423A
(en)
|
2004-04-02 |
2007-01-23 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
|
US20050256154A1
(en)
|
2004-05-04 |
2005-11-17 |
Kin-Chun Luk |
4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
|
US7102002B2
(en)
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7696224B2
(en)
|
2004-10-13 |
2010-04-13 |
Merck Patent Gmbh |
Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
|
US7151176B2
(en)
|
2004-10-21 |
2006-12-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
DE102004054216A1
(en)
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Substituted 4-amino-pyridopyrimidinones
|
DE102004054215A1
(en)
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Pyridopyrimidinonderivate
|
DE102005011058A1
(en)
|
2005-03-10 |
2006-09-14 |
Merck Patent Gmbh |
Substituted tetrahydro-pyrrolo-quinoline derivatives
|
US8383357B2
(en)
|
2005-03-16 |
2013-02-26 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
ATE477495T1
(en)
|
2005-03-16 |
2010-08-15 |
Osi Pharm Inc |
BIOLOGICAL MARKERS PREDICTIVE OF CANCER RESPONSIVENESS TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS
|
DE102005015253A1
(en)
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets
|
DE102005017259A1
(en)
|
2005-04-14 |
2006-10-19 |
Merck Patent Gmbh |
purine derivatives
|
US7745641B2
(en)
|
2005-04-19 |
2010-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogen-containing heterocyclic compound
|
WO2006134989A1
(en)
|
2005-06-15 |
2006-12-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Nitrogenated heterocyclic compound
|
GB0515026D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
ES2336832T3
(en)
|
2005-07-22 |
2010-04-16 |
Five Prime Therapeutics, Inc. |
COMPOSITIONS AND PROCEDURES TO TREAT DISEASES WITH FGFR FUSION PROTEINS.
|
EP1917015A1
(en)
|
2005-08-16 |
2008-05-07 |
F.Hoffmann-La Roche Ag |
Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
|